A multicentre, open-label, observational local study to evaluate the LDL [low density lipoprotein]-C lowering effect of ezetimibe as prescribed in daily routine practice in the South African population

Trial Profile

A multicentre, open-label, observational local study to evaluate the LDL [low density lipoprotein]-C lowering effect of ezetimibe as prescribed in daily routine practice in the South African population

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Ezetimibe (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 14 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top